Analytical Data
-
Gene name
IGFBP-2
- Application
-
Alternative Names
IBP2; IGF-BP53
-
Species
Pig
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P24853
-
Expression Region
Glu30~Gln316
-
Protein Length
Partial
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IGFBP-2 (Insulin-like Growth Factor Binding Protein 2) is a member of the IGFBP family that plays a crucial role in modulating the bioavailability and activity of insulin-like growth factors (IGFs). Research has shown that IGFBP-2 is not only involved in the regulation of cellular growth and development but also influences various physiological processes, including cell proliferation, apoptosis, and glucose metabolism. Elevated levels of IGFBP-2 have been associated with several pathological conditions, such as cancer, obesity, and metabolic syndrome, prompting interest in its therapeutic potential. Recombinant IGFBP-2 has emerged as a key tool for investigating its biological functions and interactions, facilitating the development of new strategies for disease treatment and management. Studies utilizing recombinant IGFBP-2 have provided valuable insights into its role in cancer progression and metabolic regulation, making it a promising candidate for potential interventions in related disorders. The continued exploration of IGFBP-2 through recombinant technology may yield novel biomarkers for disease risk assessment and pave the way for innovative therapeutic approaches targeting IGF signaling pathways.
